In vivo labeling kinetics of CD34+ cells during [2H2]-glucose infusion
Donor ID . | % newly produced cells, “f” × 100* . | Fractional replacement rates, klabeling/d* . | Replacement t1/2labeling, d* . | Replacement t1/2delabeling, d† . |
|---|---|---|---|---|
| D06 | 45.8 | 0.312 | 2.2 | 6.2 |
| D08 | 50.1 | 0.617 | 1.4 | 9.2 |
| D10 | 40.7 | 0.405 | 1.7 | 3.8 |
| D16 | 40.6 | 0.264 | 2.6 | 3.0 |
| D20 | 29.2 | 0.182 | 3.8 | ND |
| D21 | 28.5 | 0.168 | 4.1 | ND |
| D22 | 41.1 | 0.281 | 2.5 | ND |
Donor ID . | % newly produced cells, “f” × 100* . | Fractional replacement rates, klabeling/d* . | Replacement t1/2labeling, d* . | Replacement t1/2delabeling, d† . |
|---|---|---|---|---|
| D06 | 45.8 | 0.312 | 2.2 | 6.2 |
| D08 | 50.1 | 0.617 | 1.4 | 9.2 |
| D10 | 40.7 | 0.405 | 1.7 | 3.8 |
| D16 | 40.6 | 0.264 | 2.6 | 3.0 |
| D20 | 29.2 | 0.182 | 3.8 | ND |
| D21 | 28.5 | 0.168 | 4.1 | ND |
| D22 | 41.1 | 0.281 | 2.5 | ND |
Marrow aspirates were obtained within 2 hours (day 0) after the end of the continuous [2H2]-glucose infusion period. CD34+ cells were selected from low-density marrow cells and processed as described in “Patients, materials, and methods”. ND indicates not determined.
Values were calculated as described in “Patients, materials, and methods” and calculations for % newly produced cells (that is, one new cell added per cell division) take into consideration the mean plasma glucose enrichment. Calculations for fractional replacement rates (klabeling/day) and replacement rate t1/2labeling also take into account the number of hours of continuous [2H2]-glucose infusion.
Replacement t1/2delabeling values were estimated from the decrease in %[2H2] dA enrichment observed at week 2. Estimates of t1/2delabeling determined from the decrease [2H2] dA enrichment between week 2 and week 4 were 82 days (D08) and 17.2 days (D10) and 6 to 7 days for 3 other donors who did not have day 0 marrows evaluated.